POST Online Media Lite Edition


Novartis to help make Pfizer-Biontech COVID-19 vaccine

Christian Fernsby |
Novartis announced that it has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by supporting the production of the Pfizer-BioNTech COVID-19 Vaccine.

Article continues below


The agreement will see Novartis utilizing its aseptic manufacturing facilities at its site in Stein, Switzerland.

Under the terms of the contract manufacturing agreement, Novartis plans to take bulk mRNA active ingredient from BioNTech and fill this into vials under aseptic conditions for shipment back to BioNTech for their distribution to healthcare system customers around the world.

Subject to reaching a final agreement, Novartis plans to commence production in the second quarter of 2021 at its state-of-the art aseptic manufacturing plant in Stein. Initial shipment of finished product is expected in the third quarter.

The Novartis manufacturing team is in advanced discussions with a number of additional companies to take on manufacturing activities such as mRNA production, therapeutic protein production as well as raw material production for Covid vaccines and therapeutics. The specifics will be disclosed once those discussions are concluded.

What to read next

Pfizer and BioNTech share positive early data on mRNA vaccine candidate BNT162b2 against coronavirus
Sanofi to provide support to BioNTech in manufacturing their COVID-19 vaccine
Sanofi and BioNTech in multiyear exclusive agreement